Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BYJournal of psoriasis and psoriatic arthritis

Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials.

  • Iain B McInnes1
  • Linda Stein Gold2
  • Robert Bissonnette3
  • Mark G Lebwohl4
  • Ofelia Reyes-Servin5
  • Joseph Cafone5
  • Ya-Wen Yang6
  • Soumya D Chakravarty6,7
  • Charles Iaconangelo6
  • Shu Li5
  • Tasneam Shagroni8
  • Karissa Lozenski6
2 more authors
  • April W Armstrong9
  • Joseph F Merola10
10 affiliations
  1. 1MVLS College Office, Wolfson Medical School Building, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  2. 2Henry Ford Health System, West Bloomfield, MI, USA.
  3. 3Innovaderm Research, Montreal, QC, Canada.
  4. 4Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  5. 5Johnson & Johnson, Spring House, PA, USA.
  6. 6Johnson & Johnson, Horsham, PA, USA.
  7. 7Drexel University College of Medicine, Philadelphia, PA, USA.
  8. 8Johnson & Johnson, San Francisco, CA, USA.
  9. 9Department of Dermatology, University of California Los Angeles, Los Angeles, CA, USA.
  10. 10Department of Dermatology, and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O'Donnell School of Public Health, Dallas, TX, USA.
Read full textPDFDOICite

Abstract

Background

Icotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (≥12 years, ≥40 kg) patients with moderate-to-severe plaque psoriasis (PsO).Objective

Assess psoriatic arthritis (PsA)-specific outcomes through Week (W) 16 in a subgroup of phase-3 study participants with moderate-to-severe plaque PsO and self-reported medical history of PsA (PsO+PsA).Methods

Post-hoc analyses pooled data from ICONIC-LEAD and ICONIC-ADVANCE 1 and 2 among PsO+PsA participants randomized to once-daily icotrokinra 200 mg or placebo through W16. PsA-specific outcomes included mean change from baseline and ≥50% improvement in Patient's Global Assessment (PtGA) of PsA disease activity and Patient's Assessment of PsA Pain, and percent change from baseline in modified Nail Psoriasis Severity Index (mNAPSI). P values are nominal.Results

Analyses included 216 participants (149 icotrokinra, 67 placebo). At W8, icotrokinra-treated participants reported greater improvements vs placebo in PtGA of PsA disease activity (-18.5 vs -4.8; P < 0.001) and PsA Pain (-17.1 vs -4.6; P < 0.001), with improvement sustained at W16 (-19.2 vs -0.8; P < 0.001; -19.5 vs -7.8; P = 0.003). At W16, greater proportions of icotrokinra-treated vs placebo-treated participants achieved ≥50% improvement in PtGA of PsA disease activity (47.0% vs 10.7%; P < 0.001) and PsA Pain (45.5% vs 16.1%; P < 0.001). At W16, icotrokinra improved mNAPSI by 41.6% (vs 118.6% worsening with placebo; P < 0.001). Adverse event rates were similar between icotrokinra and placebo.Conclusions

Icotrokinra demonstrated early, substantial improvements in participant-reported PsA activity and PsA Pain, and nail psoriasis, with a favorable safety profile through W16 in participants with PsO+PsA.

Related

  1. Exercise, physical activity, and physical fitness in psoriasis and psoriatic arthritis: an umbrella review
    Zikun Lyu, Jingshi Ma, Chenzhe Ma +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMC
  2. IFN-γ, TNF-α, IL-10, IL-17 and IL-22 secretion capacities and activation profile of T cells in psoriatic arthritis patients under disease-modifying antirheumatic drug therapy
    Sibel Goksen, Gizem Ayan, Umut Kalyoncu +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMC
  3. Extracapsular and joint-dominant hand and wrist MRI patterns in psoriatic and rheumatoid arthritis: an exploratory case-control study
    Juan Huang, Shaohui Song, Quanhong Zhang +10
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMCPMC
  4. T cells form distinct spatially restricted immune responses in synovium of patients with psoriasis arthritis and rheumatoid arthritis
    Nathalie J. Behr, Julio Ramírez, Ana B. Azuaga +6
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMCCrossref
  5. Regulatory T cell dysfunction and therapeutic advances in rheumatoid arthritis, psoriasis, vitiligo, and systemic lupus erythematosus
    Yanyang Liang, Haiyan Feng, Ying Wang +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossref

Cite

BibTeXRIS
BibTeX
@article{mcinnes2026icotrokinra,
  title = {{Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials.}},
  author = {Iain B McInnes and Linda Stein Gold and Robert Bissonnette and Mark G Lebwohl and Ofelia Reyes-Servin and Joseph Cafone and Ya-Wen Yang and Soumya D Chakravarty and Charles Iaconangelo and Shu Li and Tasneam Shagroni and Karissa Lozenski and April W Armstrong and Joseph F Merola},
  journal = {Journal of psoriasis and psoriatic arthritis},
  year = {2026},
  month = oct,
  doi = {10.1177/24755303261494526},
  url = {https://europepmc.org/article/MED/42898453},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials.
AU  - Iain B McInnes
AU  - Linda Stein Gold
AU  - Robert Bissonnette
AU  - Mark G Lebwohl
AU  - Ofelia Reyes-Servin
AU  - Joseph Cafone
AU  - Ya-Wen Yang
AU  - Soumya D Chakravarty
AU  - Charles Iaconangelo
AU  - Shu Li
AU  - Tasneam Shagroni
AU  - Karissa Lozenski
AU  - April W Armstrong
AU  - Joseph F Merola
PY  - 2026
DA  - 2026/10/18
JO  - Journal of psoriasis and psoriatic arthritis
DO  - 10.1177/24755303261494526
UR  - https://europepmc.org/article/MED/42898453
AB  - Background  Icotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (≥12 years, ≥40 kg) patients with moderate-to-severe plaque psoriasis (PsO).Objective  Assess psoriatic arthritis (PsA)-specific outcomes through Week (W) 16 in a subgroup of phase-3 study participants with moderate-to-severe plaque PsO and self-reported medical history of PsA (PsO+PsA).Methods  Post-hoc analyses pooled data from ICONIC-LEAD and ICONIC-ADVANCE 1 and 2 among PsO+PsA participants randomized to once-daily icotrokinra 200 mg or placebo through W16. PsA-specific outcomes included mean change from baseline and ≥50% improvement in Patient's Global Assessment (PtGA) of PsA disease activity and Patient's Assessment of PsA Pain, and percent change from baseline in modified Nail Psoriasis Severity Index (mNAPSI). P values are nominal.Results  Analyses included 216 participants (149 icotrokinra, 67 placebo). At W8, icotrokinra-treated participants reported greater improvements vs placebo in PtGA of PsA disease activity (-18.5 vs -4.8; P < 0.001) and PsA Pain (-17.1 vs -4.6; P < 0.001), with improvement sustained at W16 (-19.2 vs -0.8; P < 0.001; -19.5 vs -7.8; P = 0.003). At W16, greater proportions of icotrokinra-treated vs placebo-treated participants achieved ≥50% improvement in PtGA of PsA disease activity (47.0% vs 10.7%; P < 0.001) and PsA Pain (45.5% vs 16.1%; P < 0.001). At W16, icotrokinra improved mNAPSI by 41.6% (vs 118.6% worsening with placebo; P < 0.001). Adverse event rates were similar between icotrokinra and placebo.Conclusions  Icotrokinra demonstrated early, substantial improvements in participant-reported PsA activity and PsA Pain, and nail psoriasis, with a favorable safety profile through W16 in participants with PsO+PsA.
SN  - 2475-5303
SN  - 2475-5311
ER  -